Side effects of 131I for ablation and treatment of well-differentiated thyroid carcinoma

Thyroid Cancer (Second Edition): A Comprehensive Guide to Clinical Management

Volumn , Issue , 2006, Pages 459-483

  Van Nostrand, Douglas ^a   Freitas, John ^b,c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b ST JOSEPH MERCY HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349112513     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-995-0_52     Document Type: Chapter

References (141)

1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87:171-182.
2. Alexander C, Bader JB, Schaefer A, et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39:1551-1554.
3. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82:3637-3642.
4. Holmquest DL, Lake P. Sudden hemorrhage in metastatic thyroid carcinoma of the brain during treatment with iodine-I31. J Nucl Med 1976; 17:307-309.
5. Datz FL. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J Nucl Med 1986; 27:637-640.
6. Hurley JR, Becker DV. The use of radioiodine in the management of thyroid cancer. In Freeman LM, Weissman HS, editors. Nuclear Medicine Annual 1983. New York: Raven Press, 1983:329-384.
7. Grayson RR. Factors which influence the radioactive iodine thy-roidal uptake test. Am J Med 1960; 24:397-415.
8. Bedikian AY, Valdivieso M, Heilbrun LK, et al. Glycerol: a successful alternative to dexamethasone for patients receiving brain irradiation for metastatic disease. Cancer Treat Rep 1978; 62:1081-1083.
9. Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follic-ular thyroid cancer: Impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14:1063-1075.
10. Zettinig G, Hanselmayer G, Fueger B, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med 2002; 29:1428-1432.
11. Bakheet SMB, Hammami MM, Hemidan A, et al. Radioiodine secretion in tears. J Nucl Med 1998; 39:1452-1454.
12. Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001; 42:738-743.
13. Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002; 87:5817-5820.
14. Burns JA, Morgenstern KE, Cahill KV, et al. Nasolacrimal obstruction secondary to I-131 therapy. Ophthal Plast Reconstr Surg 2004; 20:126-129.
15. Schiff L, Stevens CD, Molle WE, et al. Gastric (and salivary) excretion of radioiodine in man (preliminary report). J Natl Cancer Inst 1947; 7:349-354.
16. Rice DH. Advances in diagnosis and management of salivary gland diseases. West J Med 1984; 140:238-249.
17. Myant NB. Iodine metabolism of salivary glands. Ann NY Acad Sci 1960; 85:208.
18. Freinkel N, Ingbar SH. Concentration gradients for inorganic I-131 and chloride in mixed human saliva. J Clin Invest 1953; 32: 1077-1084.
19. Honour AJ, Myant NB, Rowlands EN. Secretion of radioiodine in digestive juices and milk in man. Clin Sc 1952; 11:449-462.
20. Jhiang SM, Cho JY, Ryu KY, et al. An immunohistochemical study of Na+/I-symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998; 139:4416-4419.
21. Rice DH. Advances in diagnosis and management of salivary gland diseases. West J Med 1984; 140:238-249.
22. Batsakis JG. Physiology. In Cummings CW, Schuller DE, editors. Otolaryngology-Head and Neck surgery, vol. 2. St. Louis, MO: Mosby-Year Book, 1998; 1210-1222.
23. Van Nostrand DV, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well differentiated thyroid carcinoma. J Nucl Med 1986; 27:1519-1527.
24. Kahn S, Waxman A, Ramanna L, et al. Transient radiation effects following high dose I-131 therapy for differentiated thyroid cancer (DTC). J Nucl Med 1994; 35:15P.
25. Burmeister LA, du Cret RP, Mariash CN. Local reaction to radioio-dine in the treatment of thyroid cancer. Am J Med 1991; 90: 217-222.
26. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986; 59:45-51.
27. Albrecht HH, Creutzig H. Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radioiodine therapy. Fortschr Rontgenstr 1976; 125: 546-551.
28. Tubiana M, Lacour J, Monnier JP, et al. External radiotherapy and radioiodine in the treatment of 359 thyroid cancers. Br J Radiol 1975; 48:894-907.
29. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication. J Nucl Med 1984; 25:755-758.
30. Pan MS. Follow-up study of side effects for iodine-131 treatment in patients with differentiated thyroid cancer. J Nucl Med 2004; 5S: 386P.
31. Maheshwari YK, Strattton Hill C, Haynie TP, et al. Iodine-131 therapy in differentiated thyroid carcinoma: M.D. Anderson Hospital experience. Cancer 1981; 47:664-671.
32. Tollefsen HR, DeCosse JJ, Hutter RVP. Papillary carcinoma of the thyroid. A clinical and pathological study of 70 fatal cases. Cancer 1964; 17:1035-1043.
33. Lin WY, Shen YY, Wang SJ. Short-term hazards of low-dose radioio-dine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 1996; 21:780-782.
34. Brown AP, Greening W P, McCready VR, et al. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden hospital experience. Br J Radiol 1984; 57:323-327.
35. Schneyer LH, Tanchester D. Some oral aspects of radioactive iodine therapy for thyroid disease. NYJ Dent 1954; 24:308-309.
36. Mandel S, Mandel L. Persistent sialadenitis after radioactive iodine therapy: report of two cases. J Oral Maxillofac Surg 1999; 57:738-741.
37. Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys 1996; 35:535-540.
38. Spiegel W, Reiners C, Borner W. Sialadenitis following iodine-131 therapy for thyroid carcinoma. J Nucl Med 1985; 26:816.
39. Reiners C, Eichner R, Eilles C, et al. Kamera-funktionsszintigraphie der kopfspeicheldrusen nach hoch-dosierter radiojodtherapie bei schilddrusenkarzinoma patienten. In Nuklearmedizin, Schmidt HAE, Riccabona G, editors. Stuttgart, New York: Schattauer 1980; 477-481.
40. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003; 13:265-271.
41. Laupa MS, Toth BB, Keene HJ. Effect of radioactive iodine therapy on salivary flow rates and oral streptococcus mutants prevalence in patients with thyroid cancer. Oral Surg Oral Med Oral Pathol 1993; 75:312-317.
42. Busnell DL, Boles MA, Kaufman GE, et al. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med 1992; 33:2214-2221.
43. Davies AN. The management of xerostomia: a review. Eur J Cancer Care 1997; 6:209-214.
44. Nakada K, Hirata K, Ishibashi T, et al. Cevimeline hydrochloride hydate in treating salivary gland dysfunction following radioiodine therapy for thyroid cancer. J Nucl Med 2004; 45S: 17P.
45. Ericson T, Lindberg A. Clinical trial of a saliva s t imulating tablet SST. Tandjakartidningen 1982; 74:713-716.
46. Blom M, Lunderberg T. Long term follow up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Diseases 2000; 6:15-24.
47. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth. Gerodontology 1986; 5:75-99.
48. Hochberg MC, Tielsch J, Munoz B, et al. Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly; the SEE project. J Rheumatol 1998; 25: 486-491.
49. Donachi I. B iologic effects of radiation on the thyroid. In Werner SC, Ingbar SH, editors. The Thyroid New York: Harper & Row, 1978; 274-283.
50. Goolden AWG, Mallard JR, Farran HEA. Radiation sialitis following radioiodine therapy. Br J Radiol 1957; 30:210-212.
51. Kulkarni K, Kim SM, Intenzo C. Can salivary gland uptakes on a diagnostic I-131 scan predict acute salivary gland dysfunction in patients receiving radioiodine therapy for thyroid cancer? J Nucl Med 2004; 5S:291P.
52. Shaw LM, Bonner HS, Schuchter L, et al. Pharmacokinetics of ami-fostine: effects of dose and method of administration. Semin Oncol 1999; 26:34-36.
53. Werner-Wasik M. Future development of amifostine as a radiopro-tectant. Semin Oncol 1999; 26:129-1234.
54. Dorr RT, Holmes BC. Dosing considerations with amifostine: a review of the literature and clinical experience. Semin Oncol 1999; 26: 108-119.
55. Hall P, Holm LE, Lundell G, Ruden BI. T umors after radiotherapy for thyroid cancer. Acta Oncol 1992; 31:403-407.
56. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Salivary gland protection by S-2-(3-amiopropylamino)-ethylphosphorothioic acid (ami-fostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double blind multi-arm trial. Cancer Biother Radiopharm 1999; 13:337-347.
57. Levy HA, Park CH. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer. Clin Nucl Med 1987; 12:303-307.
58. Freitas JE, Gross MD, Ripley S, Shapiro B. Radionuclide diagnosis and therapy of thyroid cancer; c urrent status report. Semin Nucl Med 1985; 15:106-131.
59. Nakada K, Ishibashi T, T a k e i K, et al. Does lemon candy decrease salivary gland damage following radioiodine therapy for thyroid cancer? J Nucl Med 2005; 46:261-266.
60. Varma VM, Dai WL, Henkin RI. Taste dysfunction in patients with thyroid cancer following treat with I-131. J Nucl Med 1992; 33:996.
61. Maier H, Bihl H. Effect of radioactive iodine therapy on parotid gland function. Acta Otolaryngol 1987; 103:318-324.
62. Norby EH, Neutze JH, Van Nostrand D, et al. Nasal radioactive iodine uptake: a prospective study of frequency, intensity and pattern. J Nucl Med 1990; 31:52-54.
63. Levenson D, Coulec S, Sonnenberg M, et al. Peripheral facial nerve palsy after high-dose radioiodine therapy in patients with papillary thyroid carcinoma. Ann Intern Med 1994; 120:576-578.
64. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States in 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation Study. Cancer 2000; 89:202-217.
65. Goolden AWG, Kam KC, Fitzpatrick ML, Munro AJ. Oedema of the neck after ablation of the thyroid with radioactive iodine. Br J Radiol 1986; 59:583-586.
66. Cooper DS, Ridgway EC, Maloof F. Unusual types of hyperthy-roidism. Clin Endocrinol Metab 1978; 7:199-220.
67. Smith R, Blum C, Benua RS, Fawwaz R. Radioactive iodine treatment of metastatic thyroid carcinoma with clinical thyrotoxicosis. Clin Nucl Med 1985; 10:874-875.
68. Ikejiri K, Furuyama M, Muranaka T, et al. Carcinoma of the thyroid manifested as hyperthyroidism caused by functional bone metastasis. Clin Nucl Med 1997; 22:227-230.
69. Trunnell JB, Marinelli LD, Duffy BJ Jr., et al. The treatment of metastatic thyroid cancer with radioactive iodine: credits and debits. J Clin Endocrinol 1949; 9:1138-1152.
70. Cerletty JM, Listwan WJ. Hyperthyroidism due to functioning metastatic thyroid carcinoma. Precipitation of thyroid storm with therapeutic radioactive iodine. JAMA 1979; 242:269-270.
71. Winslow CP, Meyers AD. Hypocalcemia as a complication of radioio-dine therapy. Am J Otolaryngol 1998; 19:401-403.
72. Glazebrook GA. Effect of decicurie prescribed activity of radioactive I-131 on parathyroid function. Am J Surg 1987; 154:368-373.
73. Lee TC, Harbert JC, Dejter SW, et al. Vocal cord paralysis following I-131 ablation of a postthyroidectomy remnant. J Nucl Med 1985; 26: 49-50.
74. Pochin EE. Radioiodine treatment of thyroid cancer. In Hahn PF, editor. Therapeutic Use of Artificial Radioisotopes. New York: John Wiley & Sons, 1956; 195.
75. Fajardo L. G LF, Berthrong M, Anderson, editors. Radiation Pathology. Oxford: University Press, 2001.
76. Rall JE, Alpers JB, Lewallen CG, et al. Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab 1957; 17: 1263-1276.
77. Aldrich LB, Sisson JC, Grum CM. Pulmonary function in thyroid carcinoma metastatic to the lung. J Endocrinol Invest 1987; 10:111-116.
78. Menzel C, Grunwald F, Schomburg A, et al. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996; 37:1496-1503.
79. Bennett DE, Million RR, Ackerman IV. Bilateral radiation pneu-monitis. A complication of the radiotherapy of bronchogenic carcinoma. Cancer 1969; 23:1001-1018.
80. Fulkerson WJ, McLendon RE, Prosnitz LR. Adult respiratory distress syndrome after limited radiotherapy. Cancer 1986; 57:1941-1946.
81. Monson JM, Stark P, Reily JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 1998; 82:842-850.
82. Morgan GW, Pharm B, Breit SN. Radiation and the lung. Int J Radiat Oncol Biol Phys 1995; 31:361-369.
83. Choi NC, Kanarek DJ, Kazemi H. Physiologic changes in pulmonary function after thoracic radiotherapy for patients with lung cancer and role of regional pulmonary function studies predicting postradio-therapy pulmonary function before radiotherapy. Cancer Treat Symp 1985; 2:119-130.
84. Mah K, Van Dyk J, Keane T, Poon P Y. Acute radiation-induced pulmonary damage: a clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13:179-188.
85. Smith JC. Radiation pneumonitis. A review. Am Rev Respir Dis 1963; 87:647-665.
86. Carmel RJ, Kaplan HS. Mantle irradiation for Hodgkin's disease. An analysis of technique, tumor eradication and complications. Cancer 1976; 37:2813-2825.
87. Fryer CJH, Fitzpatrick PJ, Rider WD, et al. Radiation pneumonitis: experience following a large single dose of radiation. Int J Radiat Oncol Biol Phys 1978; 4:931-936.
88. McDonald S, Rubin P, Philips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995; 31: 1187-1203.
89. Fowler JF, Travis EL. The radiation pneumonitis syndrome in half-body radiation therapy. Int J Radiat Oncol Biol Phys 1978; 4: 1111-1113.
90. Keane T, Van Dyk J, Rider WD. Idiopathic interstitial pneumonia following bone marrow transplantation. The relationship with total body irradiation. Int J Radiat Oncol Biol Phys 1981; 7:1365-1370.
91. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977; 86:81-92.
92. Leeper R. Controversies in the treatment of thyroid carcinoma: the New York Memorial Hospital approach. Thyroid Today 1982; 4:1-6.
93. Leeper RD. The effect of I-131 therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endo-crinol Metab 1973; 36:1143-1152.
94. Samuel AM, Unnikrishnan TP, Baghel NS, Rajashekharrao B. Effect of radioiodine therapy on pulmonary alveolar-capillary membrane integrity. J Nucl Med 1995; 36:783-787.
95. Schlumberger M, Arcangioli O, Piekarski JD, et al. Detection of and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988; 29: 1790-1794.
96. Hindiè E, Melliere D, Lange F, et al. Functioning pulmonary metas-tases of thyroid cancer: does radioiodine influence the prognosis? J Nucl Med 2003; 30; 974-981.
97. Nemec J, Zamrazil V, Pohunkova D, Roohling S. Radioiodide treatment of pulmonary metastases of differentiated thyroid cancer; results and prognostic factors. Nuklearmedizin 1979; 18:86-90.
98. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma: study of 58 cases with implications for the primary tumor treatment. Cancer 1984; 53:982-992.
99. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985; 60:376-380.
100. Leeper RD, Shimaoka K. Treatment of metastatic thyroid cancer. Clin Endocrinol Metab 1980; 9:383-404.
101. Quimby ES, Feitelberg S, Laughlin JS, et al. NCRP Report 37: Precautions in the management of patients who have received therapeutic amounts of radionuclides. Washington, DC: National Council on Radiation Protection, 1970.
102. US Nuclear Regulatory Commission 1997 Criteria for release of individuals administered radioactive materials. Federal Reg 1997; 62: 4120.
103. Marcus CS, Siegel JA. NRC absorbed dose reconstruction for family members of I-131 therapy patient: case study and commentary. J Nucl Med 2004; 45:13N-16N.
104. Kinuya S, Hwang E, Ikeda E, et al. Mallory-Weiss Syndrome caused by iodine-131 therapy for metastatic thyroid carcinoma. J Nucl Med 1997; 38:1831-1832.
105. Balan KK, Raouf AH, Critchley M. Outcome of 249 patients attending a nuclear medicine department with well-differentiated thyroid cancer; a 23 year review. Br J Radiol 1994; 67:283-291.
106. Dobyns BM, Maloof F. The study and treatment of 119 cases of carcinoma of the thyroid with radioactive iodine. J Clin Endocrinol 1951; 11:1323-1360.
107. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003; 44:451-456.
108. Grunwald F, Schomburg A, Menzel C, et al. Blood count changes after radioiodine treatment in thyroid carcinoma. Med Klin 1994; 89: 522-528.
109. Haynie T, Beierwaltes W. Hematologic changes observed following therapy for thyroid carcinoma. J Nucl Med 1963; 4:85-91.
110. Keldsen N, Mortensen BT, Hansen HS. Bone marrow depression due to I-131 treat of thyroid cancer. Ugeskr Laeger 1988; 50: 2817-2819.
111. Matthies A, Bender H, Distelmaier M, et al. Efficacy and side effects of high dose iodine-131 therapy in metastatic thyroid carcinoma. J Nucl Med 2004; 45S:189P.
112. Petrich T, Widjaja A, Musholt TJ, et al. O utcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side effects and influence of age. Eur J Nucl Med 2001; 28:203-208.
113. Robeson WR, Ellwood JE, Margulies P, Margouleff D. O utcome and toxicity associated with maximum safe dose radioiodine treatment of metastatic thyroid cancer. Clin Nucl Med 2002; 27:556-666.
114. Schober O, Gunter HH, Schwarzrock R, Hundeshagen H. Hamatologische langzeitveranderungen bei der Radiojodtherapie des Schilddrusenkarzinoms. Strahlenther Onkol 1987; 163; 464-474.
115. Schumichen C, Schmitt E, Scheuffele C. Influence of the therapy concept onto the prognosis of thyroid carcinoma. Nuklearmedizin 1983; 22:97-105.
116. Kuhn JM, Rieu M, Wolf LM, et al. Hematologic repercussions of disorders of thyroid secretion. Presse Med 1984; 13:421-425.
117. Donate RM, Gallagher NI. Hematologic alteration associated with endocrine disease. Med Clin N Am 1968; 52; 231-241.
118. Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab 1989; 69:186-190.
119. Vini L, Hyer S, Al-Saadi A, et al. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002; 78:92-93.
120. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996; 37:606-612.
121. Dottorini ME, Lomuscio G, Mazzucchelli L, et al. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med1995; 36:21-27.
122. Wichers M, Benz E, Palmedo H, et al. Testicular function after radiodi-odine therapy for thyroid carcinoma. E ur J Nucl Med 2000; 27: 503-507.
123. Hyer S, Vini L, O'Connell M, et al. Testicular dose and fertility in men following I (131). therapy for thyroid cancer. Clin Endocrinol 2002; 56:755-758.
124. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994; 35:1418-1422.
125. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent fertility and birth histories of children and adolescents treated with I-131 for thyroid cancer. J Nucl Med 1976; 17:460-464.
126. Maxon HR III, Smith HD. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clinics North Am 1990; 19:685-718.
127. Bitton R, Sachmechi I, Benegalrao Y, Schneider BS. Leukemia after a small dose of radioiodine for metastatic thyroid cancer. J Clin Endocrinol Metab 1993; 77:1423-1426.
128. de Vathaire F, Schlumberger M, Delisle MJ, et al. Leukaemias and cancers following iodine-131administration from thyroid cancer. Br J Cancer 1997; 75:734-739.
129. Hall P, Holm LE, Lundell G, et al. Cancer risks in thyroid cancer patients. Br J Cancer 1991; 64:159-163.
130. Pochin EE. Radioiodine therapy of thyroid cancer. Semin Nucl Med 1971; 1:503-515.
131. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638-1644.
132. Berthe E, Henry-Amar M, Michels JJ, et al. Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2004; 31:685-691.
133. Wiseman JC, Hales IB, Joasoo A. Two cases of lymphoma of the parotid gland following ablative radioiodine therapy for thyroid carcinoma. Clin Endocrinol 1982; 17:85-89.
134. Rodriguez-Cuevas S, Ocampo LB. A case report of mucoepidermoid carcinoma of the parotid gland developing after radioiodine therapy for thyroid carcinoma. Eur J Surg Oncol 1995; 21:692.
135. Spitzberg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 1998; 83:1746-1751.
136. Hammami MM, Bakheet S. Radioiodine breast uptake in non-breast feeding women. Clinical and scintigraphic characteristics. J Nucl Med 1996; 37:26-31.
137. Adjadj E, Rubino C, Shamsaldim A, et al. The risk of multiple primary breast and thyroid carcinomas. Cancer 2003; 98: 1309-1317.
138. Mazzaferri EL, Young RL, Oertel JE, et al. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 1977; 56: 171-196.
139. Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic thyroid carcinoma treated with radioiodine. World J Surg 1994; 18:600-604.
140. Tuttle RM, Pentlow K, Qualey R, et al. Empiric radioactive iodine (RAI) dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with metastatic thyroid cancer. (abstract #177). 74th Annual meeting, American Thyroid Association, Los Angeles CA, October 10-13, 2002, p 198.
141. Atkins FB, Van Nostrand D, Kulkarni K, et al. The frequency with which empiric amounts of radioiodine "over-" or "under-" treat patients with metastatic well-differentiated thyroid cancer. J Nucl Med 2005; 46:129P.